Alsheekh Ahmad, Hingorani Anil, Marks Natalie, Ostrozhynskyy Yuriy, Ascher Enrico
Total Vascular Care, NY, USA.
Vascular. 2017 Jun;25(3):249-252. doi: 10.1177/1708538116667325. Epub 2017 Apr 14.
Background The development and use of minimally invasive procedures provide improved options for the management of symptoms of chronic venous insufficiency. While many patients with iliac venous occlusive disease and superficial venous insufficiency improve with combined iliac venous stenting and correction of superficial venous reflux, some patients have symptoms which persist. The goal of this study was to identify clinical factors related to persistent symptoms in patients with leg swelling after treatment of both iliac vein stenting and thermal ablation. Methods This observational study analyzed data for patients who underwent both iliac vein stent placement as well as endovenous ablation (either RFA or EVLT) as a management for chronic venous insufficiency between February 2012 and February 2014. Follow-up was performed after completion of both procedures and inquiring for improvement of swelling. Statistical analysis performed using Chi-square and student's t-test. Results Of the total 173 patients who underwent both endovenous closure and iliac vein stent placements, 55 (31.8%) patients were men; 29 (16%) patients stated they had no improvement after these procedures. The average age of patients who did not improve was 68.8 (±16.7 SD) years and 66.2 (±13.3 SD) years for patients who improved. Over all, the classification of the presenting symptoms by CEAP classification demonstrated 25.4%, 53.2%, 5.8%, and 15.6%, for C3-C6, respectively. There was no correlation with failure to improve the swelling with: age ( P = .44), gender ( P = .33), presenting symptom ( P = .67), use of calcium channel blockers ( P = .85), nitroglycerin ( P = .86), Plavix ( P = .07), aspirin ( P = .55), Synthyroid ( P = .55), Coumadin ( P = .14), angiotensin receptor blocker ( P = .81), β Blockers ( P = .61), angiotensin converting enzyme inhibitors ( P = .88), furosemide 40 mg ( P = .74), hydrochlorothiazide 12.5 mg ( P = .07), hydrochlorothiazide 25 mg ( P = .48), and EVLT vs. RFA ( P = .91). The use of furosemide (20 mg) was associated with continued swelling ( P = .01). The use of dual diuretics (furosemide and hydrochlorothiazide) was associated with persistent swelling even after these combined endovenous procedures P = .03). Conclusion These preliminary data suggest that the treatment with diuretics may be associated with failure to relieve lower extremity swelling despite combined endovascular therapy for chronic venous insufficiency.
微创治疗方法的发展与应用为慢性静脉功能不全症状的管理提供了更好的选择。虽然许多髂静脉闭塞性疾病和浅静脉功能不全患者在髂静脉支架置入术联合浅静脉反流矫正术后症状有所改善,但仍有部分患者症状持续存在。本研究的目的是确定在髂静脉支架置入术和热消融治疗后腿部肿胀患者中与持续症状相关的临床因素。
本观察性研究分析了2012年2月至2014年2月期间接受髂静脉支架置入术及静脉内消融(射频消融或腔内激光治疗)以治疗慢性静脉功能不全的患者数据。在两项手术完成后进行随访,并询问肿胀情况是否改善。采用卡方检验和学生t检验进行统计分析。
在总共173例接受静脉内闭合术和髂静脉支架置入术的患者中,55例(31.8%)为男性;29例(16%)患者表示这些手术后症状未改善。未改善患者的平均年龄为68.8(±16.7标准差)岁,改善患者的平均年龄为66.2(±13.3标准差)岁。总体而言,根据CEAP分类法,C3 - C6级的首发症状分类分别为25.4%、53.2%、5.8%和15.6%。肿胀未改善与以下因素无关:年龄(P = 0.44)、性别(P = 0.33)、首发症状(P = 0.67)、使用钙通道阻滞剂(P = 0.85)、硝酸甘油(P = 0.86)、氯吡格雷(P = 0.07)、阿司匹林(P = 0.55)、左甲状腺素(P = 0.55)、华法林(P = 0.14)、血管紧张素受体阻滞剂(P = 0.81)、β受体阻滞剂(P = 0.61)、血管紧张素转换酶抑制剂(P = 0.88)、40毫克速尿(P = 0.74)、12.5毫克氢氯噻嗪(P = 0.07)、25毫克氢氯噻嗪(P = 0.48)以及腔内激光治疗与射频消融(P = 0.91)。使用速尿(20毫克)与持续肿胀相关(P = 0.01)。即使在这些联合静脉内手术后,使用联合利尿剂(速尿和氢氯噻嗪)也与持续肿胀相关(P = 0.03)。
这些初步数据表明,尽管对慢性静脉功能不全进行了联合血管内治疗,但利尿剂治疗可能与未能缓解下肢肿胀有关。